Ovid Therapeutics Inc.
NASDAQ:OVIDBiotechnology
-$0.11 today
- Market cap
- $426.53M
- Beta
- 0.18
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$0.33
Volume 2.16M
Average 3.07M
OVID Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Ovid Therapeutics Inc.NASDAQ: OVID
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin growth accelerates
Q1 FY2026 selling, general & admin of $6.67M rose 10.7% year over year, ahead of the -6.4% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 3.8% from the prior quarter. Over 3 fiscal years it compounded at -9.4% a year.
Context
- Selling, general & admin amounted to 332.4% of revenue in FY2025, down 4205.2 pp from a year earlier.
- Selling, general & admin increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 9 analysts of $23.5M (-2.5%) for the fiscal year ending Dec 2026, a step up from the -6.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $6.67M+3.8% QoQ
- Last fiscal yearDec 2025
- $24.11M-6.1% YoY
- LTMMar 2026
- $24.75M-6.4% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 24.11M USD
- Year-over-year change
- -6.1%
- 4-year CAGR
- -10.3%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 24.11M | -6.1% |
| FY2024 | 2024-12-31 | 25.68M | -13.2% |
| FY2023 | 2023-12-31 | 29.59M | -8.8% |
| FY2022 | 2022-12-31 | 32.43M | -12.9% |
| FY2021 | 2021-12-31 | 37.23M | — |
Selling, General & Admin vs competitors
How OVID compares with its peers on the latest reported figures
- OVID's LTM Mar 2026 selling, general & admin of $24.75M is the lowest of the 11 companies compared; the peer median is $61.84M.
- Its year-over-year change of -6.4% is the 9th highest of 11, against a peer median of +6.9%.
- Selling, general & admin amounts to 347.5% of revenue for OVID, versus a peer median of 110.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $350.27M | +5.7% | +7.9% | 52.3% | |
| LTM Mar 2026 | $79.08M | +23.9% | +14.3% | 110.1% | |
| LTM Mar 2026 | $75.11M | -30.1% | +13.7% | — | |
| LTM Mar 2026 | $73.88M | +132.8% | +55.6% | 508.1% | |
| LTM Mar 2026 | $71.21M | +35.2% | +19.9% | 222.0% | |
| LTM Mar 2026 | $52.46M | -2.3% | +4.4% | 65.8% | |
| LTM Jun 2026 | $38.94M | +24.4% | -1.0% | 709.8% | |
| LTM Mar 2026 | $36.17M | -2.1% | +6.6% | 99.1% | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $35.46M | -13.0% | +55.9% | — |
| LTM Mar 2026 | $27.57M | +8.0% | +40.7% | — | |
| LTM Mar 2026 | $24.75M | -6.4% | -9.4% | 347.5% | |
| Peer median (excluding OVID) | $61.84M | +6.9% | +14.0% | 110.1% | |
Competitors are the stored peer set for OVID. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 208.38M | 1.5M | 392K | 566K | 7.25M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 300K |
| Gross Profit | 208.38M | 1.5M | 392K | 566K | 6.95M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 95.9% |
| Research & Development | 46.94M | 24.62M | 28.59M | 36.77M | 25.58M |
| Selling, General & Admin | 37.23M | 32.43M | 29.59M | 25.68M | 24.11M |
| Operating Expenses | 84.17M | 57.05M | 59.67M | 62.45M | 49.39M |
| Depreciation & Amortization | 237.08K | 1.38M | 568K | 613K | 300K |
| EBITDA | 124.45M | (54.17M) | (57.01M) | (57.77M) | (17.11M) |
| EBITDA Margin | 59.7% | -3604.5% | -14544.1% | -10207.1% | -236.0% |
| Operating Income | 124.21M | (55.55M) | (59.28M) | (61.89M) | (42.44M) |
| Operating Margin | 59.6% | -3696.4% | -15122.7% | -10933.7% | -585.2% |
| Interest Income | 0 | 0 | 4.9M | 3.9M | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (45.69K) | 1.38M | 6.94M | 35.45M | 25.03M |
| Income Before Tax | 124.16M | (54.17M) | (52.34M) | (26.43M) | (17.41M) |
| Pre-Tax Margin | 59.6% | -3604.7% | -13351.8% | -4670.1% | -240.1% |
| Income Tax Expense | 1.33M | 0 | 0 | 0 | 0 |
| Net Income | 122.83M | (54.17M) | (52.34M) | (26.43M) | (17.41M) |
| Net Margin | 58.9% | -3604.7% | -13351.8% | -4670.1% | -240.1% |
| EPS (Basic) | 1.78 | (0.77) | (0.74) | (0.37) | (0.24) |
| EPS (Diluted) | 1.76 | (0.77) | (0.74) | (0.37) | (0.24) |
| Weighted Avg Shares | 67.48M | 70.43M | 70.58M | 70.91M | 73.74M |
| Weighted Avg Shares (Diluted) | 68.07M | 70.43M | 70.58M | 70.91M | 73.74M |
Ovid Therapeutics Inc.
NASDAQ:OVID
Intrinsic Alpha fair value
Locked
Current Price
$2.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.